Schering Foresees Continued Growth For Vytorin Despite Generic Zocor
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of Vytorin and Zetia grew 86% in the second quarter, Schering-Plough reports.
You may also be interested in...
Schering-Plough’s Cholesterol Franchise Holds 16.4 Percent Of New Scripts
Sales of Vytorin and Zetia climb 48 percent to $1.2 billion during the first quarter.
Schering-Plough’s Cholesterol Franchise Holds 16.4 Percent Of New Scripts
Sales of Vytorin and Zetia climb 48 percent to $1.2 billion during the first quarter.
Vytorin Outpaces Crestor In Comparison Study
Schering-Plough/Merck’s ezetimibe/simvastatin combination shows better LDL cholesterol reduction than Crestor.